Key result
Early microvascular obstruction, assessed by CMR, was associated with a 66.2% occurrence of the primary composite endpoint compared to 42.4% in patients without MVO, with indicating a higher risk of adverse outcomes.
Why the study?
Does the presence of early microvascular obstruction assessed by CMR predict adverse clinical outcomes in patients reperfused by pPCI for STEMI?
Cohort (n=129)
No
Does the presence of early microvascular obstruction assessed by CMR predict adverse clinical outcomes in patients reperfused by pPCI for STEMI?
Answers are grounded in this paper and cite their sources.
Early microvascular obstruction assessed by first-pass CMR is a strong independent predictor of long-term cardiovascular morbidity at 5 years in patients after STEMI.
Early MVO, as assessed by first-pass CMR, is an independent long-term prognosticator for morbidity after AMI.
No takes yet. Share an insight, caveat, or question.
Klug et al. (2012) conducted a cohort in acute ST-elevation myocardial infarction (n=129). early microvascular obstruction (MVO) assessment by CMR vs. patients without early MVO was evaluated on composite of death, myocardial re-infarction, stroke, repeat revascularization, recurrence of ischemic symptoms, atrial fibrillation, congestive heart failure and hospitalization (HR 2.20, 95% CI 1.11-4.36, p=0.024). Early microvascular obstruction, assessed by CMR, was associated with a 66.2% occurrence of the primary composite endpoint compared to 42.4% in patients without MVO, with indicating a higher risk of adverse outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: